PL2739311T3 - Metoda leczenia szczelinowych uszkodzeń kości - Google Patents

Metoda leczenia szczelinowych uszkodzeń kości

Info

Publication number
PL2739311T3
PL2739311T3 PL12746235T PL12746235T PL2739311T3 PL 2739311 T3 PL2739311 T3 PL 2739311T3 PL 12746235 T PL12746235 T PL 12746235T PL 12746235 T PL12746235 T PL 12746235T PL 2739311 T3 PL2739311 T3 PL 2739311T3
Authority
PL
Poland
Prior art keywords
treating bone
bone gap
gap defects
defects
treating
Prior art date
Application number
PL12746235T
Other languages
English (en)
Inventor
Xiaodong Li
Hua Zhu Ke
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of PL2739311T3 publication Critical patent/PL2739311T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL12746235T 2011-08-04 2012-08-02 Metoda leczenia szczelinowych uszkodzeń kości PL2739311T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161515191P 2011-08-04 2011-08-04
PCT/US2012/049331 WO2013019954A1 (en) 2011-08-04 2012-08-02 Method for treating bone gap defects
EP12746235.6A EP2739311B9 (en) 2011-08-04 2012-08-02 Method for treating bone gap defects

Publications (1)

Publication Number Publication Date
PL2739311T3 true PL2739311T3 (pl) 2018-08-31

Family

ID=46650942

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12746235T PL2739311T3 (pl) 2011-08-04 2012-08-02 Metoda leczenia szczelinowych uszkodzeń kości

Country Status (17)

Country Link
US (2) US10538584B2 (pl)
EP (1) EP2739311B9 (pl)
JP (4) JP6301832B2 (pl)
AU (1) AU2012290083B2 (pl)
CA (1) CA2842432C (pl)
CY (1) CY1120666T1 (pl)
DK (1) DK2739311T3 (pl)
ES (1) ES2667554T3 (pl)
HR (1) HRP20180736T1 (pl)
HU (1) HUE039786T2 (pl)
LT (1) LT2739311T (pl)
MX (1) MX355816B (pl)
NO (1) NO2739311T3 (pl)
PL (1) PL2739311T3 (pl)
PT (1) PT2739311T (pl)
SI (1) SI2739311T1 (pl)
WO (1) WO2013019954A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CA2815181C (en) * 2010-10-27 2020-09-15 William Gleason Richards Dkk1 antibodies and methods of use
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2015087187A1 (en) * 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
KR102876829B1 (ko) 2018-06-13 2025-10-27 스트리커 유로피안 오퍼레이션즈 리미티드 골편을 수집 및 처리하기 위한 장치 및 수술 시스템
EP4424337B1 (en) 2019-12-18 2025-10-01 Stryker European Operations Limited Bone fragment collector and processor

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1391707A (en) 1918-08-15 1921-09-27 Viviano Philip Automatic change-speed transmission
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (ja) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
WO1992006693A1 (en) 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
WO1994028929A1 (en) 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
EP0756628B1 (en) 1994-04-29 2007-11-14 Curis, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
DE4427221A1 (de) 1994-08-01 1996-02-08 Gsf Forschungszentrum Umwelt Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CA2220912A1 (en) 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
WO1997044461A2 (en) 1996-05-22 1997-11-27 Novopharm Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
JP2001512016A (ja) 1997-08-01 2001-08-21 ジェンセット 筋肉およびその他中胚葉組織中で発現される分泌タンパク質の５’ｅｓｔ
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
DE69934227T2 (de) 1998-06-19 2007-10-04 Mcgill University, Montreal Auf Beta-Arabinose und dessen Analoga basierte Antisense-Oligonukleotide
US6544485B1 (en) 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ATE481487T1 (de) 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
JP2002536968A (ja) 1999-01-29 2002-11-05 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的な抗体およびその使用
EP1657256B1 (en) 1999-06-09 2009-10-07 Genentech, Inc. Compositions and methods for the treatment of tumor
JP2003525611A (ja) 2000-03-02 2003-09-02 アムジェン インコーポレーテッド コルディン様−２分子およびその使用
JP2003534813A (ja) 2000-06-01 2003-11-25 アムジェン インコーポレーテッド シスチンノットポリペプチド：ｃｌｏａｋｅｄ−２分子およびその使用
EP1366156A2 (en) 2000-06-19 2003-12-03 F. Hoffmann-La Roche Ag Osteolevin gene polymorphisms
JP4451059B2 (ja) 2000-09-01 2010-04-14 ジェネンテック インコーポレイテッド 分泌及び膜貫通ポリペプチドとそれをコードする核酸
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
DE10145772A1 (de) 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA·1·-Pyrroline
BRPI0214680B1 (pt) 2001-12-06 2018-09-18 Biocontrol Systems, Inc. instrumento para uso em monitorar um produto, um ingrediente, um ambiente ou processo, instrumento para detectar emissão de luz de uma amostra e método de monitorar uma amostra de um produto, um ingrediente, um processo ou ambiente
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
AU2003223214B2 (en) 2002-03-01 2008-09-18 Celltech R & D, Inc. Methods to increase or decrease bone density
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
WO2004098491A2 (en) 2002-11-01 2004-11-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
US7642238B2 (en) 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
MXPA05009805A (es) 2003-03-14 2006-04-18 Celltech R & D Inc Ligandos para proteinas de enlace tgf-beta y usos de los mismos.
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
GB0324854D0 (en) 2003-10-24 2003-11-26 Expresson Biosystems Ltd App/ena antisense
US20050267233A1 (en) 2004-05-25 2005-12-01 Joshi Ashok V Anti-microbial handle system
WO2006015373A2 (en) 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP1981910B1 (en) 2006-01-13 2013-06-26 A Chan Holding B.V. Method for identifying inhibitor of the glypican-sclerostin interaction
EP2423226A3 (en) 2006-11-10 2012-05-30 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2460828A3 (en) 2006-11-10 2012-08-08 UCB Pharma, S.A. Antibodies and diagnostics
EP3345607B1 (en) 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
EP2114435A1 (en) 2007-02-02 2009-11-11 Novartis AG Modulators of sclerostin binding partners for treating bone-related disorders
MY149129A (en) * 2007-03-20 2013-07-15 Lilly Co Eli Anti-sclerostin antibodies
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
BRPI0820327A2 (pt) 2007-11-02 2020-10-06 Novartis Ag moléculas e métodos para modulação de proteína relacionada ao receptor de lipoproteína de baixa densidade 6 (lrp6)
CN101896201A (zh) 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
CA2815181C (en) 2010-10-27 2020-09-15 William Gleason Richards Dkk1 antibodies and methods of use

Also Published As

Publication number Publication date
SI2739311T1 (en) 2018-07-31
MX355816B (es) 2018-05-02
LT2739311T (lt) 2018-06-11
WO2013019954A1 (en) 2013-02-07
NO2739311T3 (pl) 2018-07-21
JP2019167348A (ja) 2019-10-03
CA2842432A1 (en) 2013-02-07
CY1120666T1 (el) 2019-12-11
AU2012290083A1 (en) 2014-03-13
CA2842432C (en) 2022-10-04
HRP20180736T1 (hr) 2018-06-29
HUE039786T2 (hu) 2019-02-28
EP2739311B1 (en) 2018-02-21
DK2739311T3 (en) 2018-04-23
JP6301832B2 (ja) 2018-03-28
AU2012290083B2 (en) 2017-07-20
US10538584B2 (en) 2020-01-21
ES2667554T3 (es) 2018-05-11
ES2667554T9 (es) 2018-10-01
EP2739311B9 (en) 2018-09-19
JP2014521692A (ja) 2014-08-28
PT2739311T (pt) 2018-03-26
EP2739311A1 (en) 2014-06-11
MX2014001416A (es) 2014-10-17
US20200115444A1 (en) 2020-04-16
JP2017214374A (ja) 2017-12-07
US20140271654A1 (en) 2014-09-18
JP2021183610A (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
EP2793755A4 (en) METHOD AND APPARATUS FOR REPLACING HIP
GB2487757B (en) Apparatus and method for reducing interference
EP2790897A4 (en) METHOD AND APPARATUS FOR MANUFACTURING AN OBJECT
IL231495A0 (en) A method for treating osteoporosis
ZA201400005B (en) Method for treating eczema
IL229999B (en) Device and method for improving skin
IL227679A0 (en) Method and device for skin renewal
EP2663685A4 (en) METHOD FOR OPERATING A CLOTHING TREATMENT DEVICE
ZA201208219B (en) Method for treating wasterwater
GB201111859D0 (en) Apparatus and method for controlling an apparatus
PL3703403T3 (pl) Sposób i aparat do zapisywania w pamięci podręcznej
PT2718406T (pt) Conjunto de placa de grelha para um reator de hidroconversão e sua utilização
PT2788544T (pt) Processo para a preparação de papel velho
PL2916549T3 (pl) Sposób i urządzenie do kompensacji ruchu
EP2748986A4 (en) PROCESS AND DEVICE FOR PATH SWITCHING
HUE039786T2 (hu) Csonthiány-defektusok kezelési módszere
EP2737748A4 (en) METHOD AND DEVICE FOR TRANSFER PROCESSING
SI3404041T1 (sl) Metoda za zdravljenje osteoporoze
GB201117243D0 (en) Method and apparatus for grinding
EP2723348A4 (en) METHOD FOR THE TREATMENT OF ADIPOSITAS
EP2694077A4 (en) METHOD FOR TREATING ASTHENOPY
IL228744A0 (en) A method for treating diseases related to interferon alpha
GB2496717B (en) Imaging apparatus and method for controlling same
GB201121008D0 (en) Apparatus & method
ZA201400707B (en) Method for treating schizophrenia